Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo

Xiaowen Yu(Southwest University), Li Sun(Centre for Inflammation Research)
Oncology Reports
January 16, 2017
Cited by 1


Related Papers